several large ongoing multicenter clinical trials.3 Three other trials testing whether statins as monotherapy may reverse atherosclerosis have recently been completed. [4] [5] [6] The Monitored Atherosclerosis Regression Study (MARS) and the Canadian Coronary Atherosclerosis Intervention Trial (CCAIT) both tested the effect of lovastatin on coronary atherosclerosis4'5 and demonstrated a significant slowing of progression. The trials had few major cardiovascular events. The Pravastatin, Lipids, and Atherosclerosis in the Carotids (PLAC-2) trial evaluated the effect of pravastatin in slowing early carotid atherosclerosis as measured by B-mode ultrasonography. This trial demonstrated a favorable effect on progression of intimal-medial thickness (IMT) in the common carotid artery and also showed a favorable trend for fewer coronary events. 6 A large segment of the population typically not included in previous trials are asymptomatic subjects levels between the 60th and 90th percentiles who were free of symptomatic cardiovascular disease. This report focuses on the effect of 33 to 36 months of treatment with lovastatin, a lipid-lowering agent, on both subclinical atherosclerosis and clinical cardiovascular outcome measures. Details concerning the warfarin component of the factorial design will be described in a separate publication.
Methods Design
The ACAPS was a randomized, double-blind, placebocontrolled, multicenter clinical trial conducted in asymptomatic participants to determine the effects of lovastatin and warfarin on the progression of IMT in the carotid arteries and on the rate of cardiovascular events. The study population was men and women, 40 to 79 years old, with early carotid atherosclerosis and moderately elevated LDL cholesterol. Individuals with a history of myocardial infarction (MI), stroke, or angina were excluded. A factorial design was used, and participants were randomly assigned to one of four drug combination groups: active lovastatin/active warfarin, active lovastatin/warfarin placebo, lovastatin placebo/active warfarin, and lovastatin placebo/warfarin placebo. The rationale and design for ACAPS have been published previously. 8 The a priori primary objective was to assess the effect of treatment on the average 3-year progression of a summary measure: the mean of the maximum IMT measurements from the 12 walls, near and far, of the common carotid, the bifurcation, and the internal carotid arteries on both sides of the neck. Methodological studies have shown that the use of a summary measure rather than individual IMTs markedly reduces variability and, thus, increases statistical power and that IMT measures in the near walls closely match those in the respective far walls. 9 The secondary objectives of ACAPS were to determine the treatment effects on the incidence of major atherosclerotic events, to assess the safety of the two interventions individually and in combination, to quantify treatment effects on lipoproteins and prothrombin time, and to conduct natural history studies in the double-placebo group. Another B-mode measure, the progression of the single maximum IMT, was also assessed as a secondary outcome measure. All analyses were planned to be two-sided. Subjects attending SV3 underwent a complete ultrasound examination by an ACAPS-certified ultrasonographer to determine the presence of a qualifying carotid lesion. All scans were sent to the Ultrasound Reading Center for analysis. Eligibility required that at least 1 of the 12 maximum IMTs was .1.5 mm in the common or internal carotid arteries or 1.6 mm in the bifurcation and that all IMTs were <3.5 mm. A second fasting lipid profile was also obtained at SV3.
Participants who were eligible at the completion of SV3 were enrolled in a 3-to 4-week run-in period during which they were given lovastatin placebo and open-labeled warfarin (1 mg/dL). At this time, the participants were also given open-labeled, low-dose aspirin (81 mg/d). One purpose of the run-in phase was to identify and exclude participants who took <80% of their pills. Those intolerant of aspirin remained eligible.
Participants remaining eligible at the completion of the run-in phase returned for the baseline visit and underwent a series of tests that included a physical examination, a dietary assessment, a second B-mode scan, an ECG, a slit-lamp examination, and other blood tests.
Randomization and Treatment
After verification of eligibility, consenting participants were allocated to one of the four treatment groups by blocked randomization with stratification by clinical center.
The initial dose of lovastatin was 20 mg/d, while the warfarin dose was maintained at 1 mg/d. Throughout the study, all participants were encouraged to take one 81-mg aspirin tablet daily along with their study medication unless they could not tolerate it. Everyone was instructed to take all three ACAPS medications with the evening meal.
The goal of the lovastatin treatment was to reduce LDL cholesterol to the range of 90 to 110 mg/dL (2.31 to 2.85 mmol/L) over the first two postrandomization follow-up visits at 1.5 and 3 months. At the third follow-up visit (4.5 months), the lovastatin dose was either increased to 40 mg/d if LDL cholesterol exceeded this range or decreased to 10 mg/d if it was lower. A sample of the lovastatin-placebo participants also had an upward or downward dose adjustment to maintain the double-blind design. Thereafter, LDL cholesterol was regularly monitored in all participants to ensure maintenance of acceptable levels.
Follow-up
Regular clinic visits were scheduled every 6 weeks for the first 15 months and quarterly thereafter to permit safety monitoring. Fasting lipid profiles were obtained during follow-up at 1.5, 3, 6, and 12 months and then annually. B-mode ultrasonography was conducted semiannually. ALT and urine were examined at every visit. Drug adherence was assessed by pill count and participant report of usage. The annual visits involved a brief physical examination and dietary assessment.
During the course of the study, participants with LDL cholesterol levels exceeding their age-and gender-specific 90th percentile received dietary counseling. If the dietary intervention failed to reduce the LDL cholesterol below the 90th percentile, an open-label bile acid sequestrant, cholestyramine, was added to the study medication for the duration of the trial. Conversely, if LDL cholesterol fell below 90 mg/dL, the medication dose was reduced.
All participants were originally to be followed for 3 years. Because of delays in the initiation and completion of recruitment, the last cohort of 300 enrollees was followed for only 33 months. Follow-up ended on June 30, 1993.
B-Mode Ultrasonography
The ultrasound methods and IMT measurement reproducibility have been described previously.8,10 Sonographers and B-mode image readers completed a 3-month central training and certification program before acquiring data on ACAPS participants. After a careful circumferential scan, sonographers used a high-resolution 10-MHz ultrasound system (Biosound Phase 2) to obtain longitudinal B-mode images of the arterial wall boundaries in each of the 12 defined carotid segments. The primary objective was to image and record on videotape the maximum IMT in each segment. All images were centrally analyzed by readers unaware of treatment assignment, and the maximum IMT of each segment was computed by use of locations of crosshairs placed on the wall boundaries to a precision of 0.05 mm. The mean absolute difference between 858 paired readings of the baseline mean maximum IMT performed 1 month apart before randomization was 0.11 mm. At the end of ACAPS, a sample of paired baseline and 36-month scans were reread to determine the possibility of reader drift.9 No such drift was observed.
Ultrasound Outcome Measures
The primary ultrasound outcome was the change over time of the mean maximum IMT across 12 preselected segments in the carotid arteries. A positive change over 3 years (ie, an increase in IMT) denoted progression; negative change (ie, a decrease in IMT) denoted regression. A secondary ultrasound outcome was the change over time of the single maximum IMT measurement among the same preselected carotid artery segments. There were two ultrasound examinations at baseline, one every 6 months for the next 30 months and two at the final clinic visit. Thus, participants had up to nine B-mode examinations during the trial.
Major Clinical Events
At each follow-up visit, participants were asked about hospitalizations, including possible recent MIs and strokes. ECGs, enzyme data, symptom reports, and hospital records were obtained for each suspected MI 
Statistical Analyses
The factorial design used in ACAPS is optimal if the treatment effects are additive, ie, if the effect of the combined therapies is comparable to the sum of the effects of the monotherapies.14 In such cases, comparisons are most effectively made between marginal means, for example, comparing all persons assigned to receive lovastatin (regardless of warfarin assignment) with those assigned not to receive lovastatin. The analysis plan for ACAPS involved an initial test of the assumption of additivity using Tukey's method. ' 5 If the assumption of additivity appeared to be reasonable for a given outcome measure, marginal comparisons were to be performed. If the assumption did not appear to be reasonable, the analysis plan specified pairwise comparisons of each of the three active intervention groups with the double-placebo group. In such cases, a Bonferroni adjustment of P values was to be used to control the type I error across the three pairwise comparisons.
Comparisons of the annualized progression rates for the primary and secondary summary measures of IMT were performed among treatment arms according to the two-stage analysis plan described previously. 8 The first stage consisted of computing these rates for each participant from the serial data collected across the study visits. Weighted linear regression'6 was used to compute these rates (slopes), and the weights were proportional to the inverse of the variances of the summary measures for the different examinations. Since the number of quantifiable walls was expected to vary from examination to examination, a conditional maximum likelihood approach17 was used to adjust the outcome measure for missing data and to produce appropriate variance estimates for each outcome measure. Rather than focusing only on mean differences between baseline and trial termination, the regression model allowed data from intervening examinations to contribute to the analysis and increase the statistical power.
The second stage of the analysis process consisted of weighted ANCOVAs to compare the mean progression rates among treatment groups. In these analyses, the weight for each participant's annualized progression rate was inversely proportional to the variance of that rate. Thus, participants with more follow-up examinations and more quantifiable walls across the examinations received greater emphasis in the comparisons. Two covariates were used in these analyses of the B-mode data: clinical site and the prerandomization value of the summary measure (averaged across the two baseline examinations). Separate comparisons of each of the active interventions with the placebo treatment were made with Bonferroni adjustments to control type I error for pairwise comparisons. All comparisons were by treatment allocation (intention to treat) and were two-sided.
To check the assumption of linearity implicit in basing analyses on annualized rates, Laird-Ware models18 using restricted maximum-likelihood methods'9 were employed to compare the fit of linear and nonlinear progression models. Polynomial and higher-order models for time were used to characterize nonlinear progression in these analyses, as specified in the protocol. (Fig 1) . This difference decreased slightly during the 3-year follow-up. HDL cholesterol rose by 5% in the lovastatin-treated group, from 51.7 mg/dL (1.3 mmol/L) at baseline to 54.3 (1.4 mmol/L) at 6 months (P<.0001). The lovastatin effects on LDL and HDL cholesterol did not appear to be influenced by the use of 1 mg warfarin. Regular users of aspirin had an approximately 25% greater lovastatin effect on LDL cholesterol than the nonregular users. Placebo participants regularly using aspirin had a slightly greater LDL reduction than the nonregular users.
Changes in Ultrasonographically Determined Early Carotid Atherosclerosis
A statistically significant interaction (P=.04) was detected for the primary outcome measure, the progression rate of mean maximum IMT: the observed effect of the lovastatin and warfarin combination on progression was less than the effect of lovastatin alone (Table 2) . For this reason, progression data from the four individual treatment groups, rather than marginals of the factorial design, were compared.
No statistically significant nonlinearity was found for IMT progression across the cohorts. Thus, a linear model for analyzing the 3-year progression rates was appropriate for the primary comparison of treatment effects as described in the protocol. Graphical examinations of residuals from the regressions justified the assumption of an underlying normal distribution for random error. Supplemental analyses also assessed the impact of using weighted versus nonweighted regression, using two-stage versus one-stage19 approaches, and using conditional maximum likelihood versus ignoring nonquantifiable walls. Each of these supported the analytic choices specified in the design of the study, but none affected the overall interpretation of study results. Fig 2 portrays the serial mean maximum IMTs for the lovastatin and placebo groups, excluding those assigned to active warfarin. These curves have been aligned so that the baseline values coincide. The mean maximum IMT for the lovastatin group appears to parallel the progression in the placebo group for 6 to 12 months. Beyond this time point, there was a marked decrease in mean maximum IMT. The overall annualized progression rates for the lovastatin group and the placebo group, -0.009 and 0.006 mm/y, respectively, were significantly different (P=.001, Bonferroni-adjusted; Table  2 ). The effects of lovastatin were similar in men and 
Incidence of Major Cardiovascular Events and Mortality
Fourteen of the 459 ACAPS participants in the lovastatin-placebo groups had a major cardiovascular event (4 coronary heart disease deaths, 5 strokes, and 5 nonfatal MIs) compared with 5 of the 460 participants in the lovastatin groups (all nonfatal MIs). Cumulative event curves differed significantly, with a value of P=.04 (Fig 3) .
Among the nine deaths in ACAPS, one was in a participant treated with lovastatin and eight in participants receiving lovastatin-placebo (Fig 4, P=.02 ). All six cardiovascular deaths were in the lovastatin-placebo group; the remaining three deaths were cancer deaths. There were no violent deaths.
Adverse Events
The occurrences of 19 potential adverse events were monitored during the trial. One reached nominal statistical significance for the comparison lovastatin versus lovastatin-placebo. Skin tissue deterioration was reported more often in the placebo group, 43 versus 27 (P=.05).
For the warfarin versus warfarin-placebo comparisons, the combined occurrence of muscle weakness, soreness, or cramping was more common in the placebo group, 297 versus 264 (P=.04). Unusual bleeding was slightly more common in the warfarin group: 142 versus 120 (P=.10). There was no evidence that the lovastatinwarfarin combination increased the risk of any of the 19 prespecified potential adverse events.
Monitoring of ALT showed no difference between lovastatin and lovastatin-placebo. Six participants in each group had an ALT at least 200% greater than the upper limit of normal for the local laboratory. Three of the lovastatin and two of the placebo participants went off their study medication permanently.
Discussion
Given the population studied, this trial adds new information to the ever-growing pool of data regarding lipid-lowering regimens. ACAPS is the first trial to demonstrate the benefit of lipid-lowering treatment in asymptomatic subjects with LDL cholesterol below recommended NCEP treatment levels. These findings apply to both men and women. It is also the first trial to demonstrate the effects of statins on both cardiovascular disease incidence (exclusive of cardiovascular procedures) and all-cause mortality. Finally, ACAPS is the first trial to demonstrate the validity and statistical efficiency of B-mode ultrasonography as an outcome measure of the progression of early carotid atherosclerosis in a multicenter clinical trial setting.
Lipid Lowering
The LDL cholesterol-lowering effect of lovastatin has been well established.1 21, 22 
Clinical Implications
The reversal or slowing of the typical progression of IMT in the carotid arteries is consistent with reported effects of statins on coronary atherosclerosis. These findings are consistent with the concept that atherosclerosis is a generalized condition and that one vascular bed can serve as an appropriate marker for others. ACAPS adds to the overwhelming scientific and clinical evidence that the statins have much greater lipidlowering potential than the older lipid-lowering agents. In addition, they are safe and well tolerated by asymptomatic subjects.
The primary evidence of a clinical benefit of lipidlowering in ACAPS comes from a reduction in the count of clinical events. The strength of the evidence for a reduction in cardiovascular events in ACAPS, however, should not be exaggerated. Because of the small sample size, a clinical benefit was not expected. Nonetheless, the very large relative reduction in events did yield an observed value of P=.04. This observation takes on additional meaning because two small, recent trials of pravastatin have shown similar benefits. The consistency of the findings across these trials conveys a strong message that the statins may have substantial clinical benefits to coronary patients and to those with significant subclinical atherosclerotic disease as measured by B-mode ultrasonography of the carotid arteries. Ongoing large-scale trials will determine whether the clinical benefits extend to primary prevention and to the most important outcome, all-cause mortality.
Although the standardization of B-mode ultrasonography in the typical clinical setting is less stringent than that in research projects such as ACAPS, clinical B-mode data would be adequate for the diagnosis of subclinical carotid atherosclerosis in individuals and treatment decisions. However, the use of the technique for monitoring individual treatment effects in individuals is still investigational. Furthermore, it does seem reasonable to extrapolate the ACAPS findings in subjects with subclinical atherosclerosis to patients with clinically manifest atherosclerosis. If so, the results lend support to the new NCEP guidelines for more aggressive use of lipid-lowering therapy in patients with coronary disease.40 These guidelines recommend lowering the cutoff point for initiation of treatment to 130 mg/dL (3.36 mmol/L), which was the low eligibility limit for LDL cholesterol in ACAPS.
